Prostate Cancer

At 3 years, transdermal estradiol demonstrated noninferior MFS compared with standard LHRH agonists.

The study is evaluating the safety, tolerability, whole-body distribution, and preliminary clinical activity of RAD 402 in patients with locally advanced or metastatic castration-resistant prostate cancer.

Matthias Saar, MD, discusses findings from the phase 2 INDUCTA study, evaluating the use of inductive hormonal therapy to achieve operability in patients with T4 prostate cancer.

Andrew J. Armstrong, MD, MS, highlights updated recommendations from the Prostate Cancer Working Group 4.

In this episode of The UroOnc Minute, host Adam B. Weiner, MD, is joined by Veeru Kasivisvanathan, MBBS, MSc, PhD, FRCS, to discuss the role of biparametric vs multiparametric MRI for prostate cancer detection.

The European Commission is expected to have a final decision on the application in the second quarter of 2026.

The PRIMARY2 phase 3 trial found that PSMA PET-CT in men with normal or equivocal MRI results safely halved the number of prostate biopsies, maintained non-inferior detection of clinically significant cancer, and reduced insignificant cancer diagnosis by more than half.

Neha Vapiwala, MD, pointed to the shift toward more personalized approaches and the expanding role of radiopharmaceutical therapies.

Topline results from the TALAPRO-3 study showed that adding talazoparib to enzalutamide improved rPFS for patients with HRR-mutated mCSPC.

Enolen implants demonstrated minimal systemic drug exposure and early signals of tumor volume reduction in localized prostate cancer.

The OPTIMUM randomized trial demonstrated that microultrasonography-guided biopsy is noninferior to MRI fusion-guided biopsy for detecting clinically significant prostate cancer, with a streamlined in-office workflow, a manageable learning curve, and substantially lower cost that may help address diagnostic access gaps worldwide.

Alicia Morgans, MD, MPH, shares findings from a real-world study assessing darolutamide or abiraterone in combination with ADT plus docetaxel for mHSPC.

Lutetium-177 rosopatamab tetraxetan demonstrated an acceptable safety and tolerability profile with no new safety signals in patients with PSMA-positive mCRPC.

Results from the AMPLIFY trial are intended to support an FDA submission seeking approval of 64Cu-SAR-bisPSMA as a diagnostic imaging agent for BCR of prostate cancer.

According to Lantheus, Pylarify TruVu is formulated to improve product stability at higher radioactive concentrations, facilitating more efficient manufacturing and distribution.

Fred Saad, MD, FRCP, highlights the background and key findings from the phase 1 PAnTHa study.

“Biochemical responses were seen at all dose levels, with an overall PSA50 response of 62% and a PSA90 response of 40%," according to Fred Saad, CQ, MD, FRCS, FCAHS.

Karim Fizazi, MD, PhD, reported that the 9-year prostate cancer-specific survival rate was 90% (95% CI, 86-94) in patients receiving cabazitaxel vs 89% (95% CI, 84-93) in patients not receiving cabazitaxel.

"Capivasertib in combination with abiraterone represents a potential first-in-class targeted treatment for patients with this now PTEN-defined metastatic APMN,” said Daniel J. George, MD.

Stacy Loeb, MD, MSc, discusses a study evaluating levels of at microplastics and nanoplastics in prostate cancer tissue.

Enrique Gallardo, MD, discusses the final overall survival (OS) results from the EORTC 1333/PEACE-3 trial of enzalutamide plus radium-223 in patients with metastatic castration-resistant prostate cancer.

"Enzalutamide plus radium-223 is an option in first-line treatment for mCRPC patients with bone metastases," said Enrique Gallardo, MD.

Median OS was 28 months (95% CI, 13-NR) in arm 1, 37 months (95% CI, 26-NR) in arm 2, and 68 months (95% CI, 38-NR) in arm 3.

Austin Kirschner, MD, PhD, discusses the recent US commercial launch of the PROSTOX Standard test and its potential to inform radiation treatment decisions for patients with prostate cancer.